Needham & Company Upgrades Hologic (HOLX) to Buy Following Cynosure Deal
Tweet Send to a Friend
Needham & Company upgraded Hologic (NASDAQ: HOLX) from Hold to Buy with a price target of $46.00 after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
